Kevin Honeycutt was named CEO and president of Alliance for Cancer Gene Therapy in December 2018 and elected to its board of directors in June 2022. His principal role as Chief Executive Officer is to help realize and enhance the vision of the organization’s 2001 co-founders, Barbara Netter and her late husband Edward, and to spearhead the organization’s focus on solving the next generation of challenges brought by metastatic cancers and solid tumors while continuing to build organizational alliances and joint ventures.

Prior to joining the organization, Mr. Honeycutt served as the president and CEO of the Avon Breast Cancer Crusade, executive director of the Avon Foundation for Women and in a variety of consulting roles through his firm, Honeycutt Partners, including projects for the American Diabetes Association, the New Venture Fund, the Entertainment Industry Foundation, the San Francisco AIDS Foundation and other leading nonprofit organizations.

Mr. Honeycutt serves on the Board of Directors of the Global Cancer Institute and Friends of Mozart and is a member of the National Council of the Eastman School of Music at the University of Rochester, Rochester, New York. He is a past Board member of the Jonsson Cancer Center Foundation, University of California, Los Angeles.